Hinduja Hospital, MRC & Ibhar Tech Partner For AMC & IPC Programs

This initiative aims to empower healthcare professionals to implement WHO and CDC-endorsed strategies effectively.

In a move aimed at digitalizing its Antimicrobial Stewardship (AMS) and Infection Prevention & Control (IPC) programs, PD Hinduja Hospital and Medical Research Centre (MRC) has joined forces with Ibhar Technologies.

This collaboration signifies a step towards leveraging Artificial Intelligence (AI) and Machine Learning (ML) capabilities to elevate healthcare standards, with a focus on enhancing patient safety and clinical outcomes.

Global Challenge of AMR

India is facing a concerning projection of 4.7 million deaths due to Antimicrobial Resistance (AMR) by 2050, with high rates of bacterial infections making it a global hotspot for such issues.

The mortality rate of 417 per 100,000 from infectious diseases further underscores the urgency of addressing this issue. In 2019 alone, 297,000 deaths were directly linked to AMR, highlighting the critical need for effective interventions.

In response to these challenges, PD Hinduja Hospital & MRC has adopted Ibhar's AMS solutions to enhance infection prevention and control practices in healthcare settings.

Leveraging mobile and web-based tools, this initiative aims to empower healthcare professionals to implement WHO and CDC-endorsed strategies effectively.

Robust IPC programs have been shown to reduce Healthcare-associated Infections (HAIs) by 70%, emphasizing the pivotal role of Ibhar's solutions in ensuring patient safety and advancing global healthcare standards.

Streamlined Process with Real-time Dashboards

The Ibhar tool for infection prevention and control streamlines the entire process by facilitating the identification of necessary actions, recording current statuses, and efficient planning for addressing any outstanding issues.

Real-time dashboards provide a comprehensive view of non-compliant contributors, enabling departments, quality teams, and management to collaboratively develop and implement efficient practices swiftly.

Individual department heads are empowered to understand requirements, record current statuses, and seamlessly plan necessary actions. This integrated approach also enables regular audits and tracking of key performance indicators (KPI), enhancing organizational compliance and accountability.

The implementation of this technology at PD Hinduja Hospital & MRC is supported by Pfizer and the Association of Healthcare Providers India (AHPI).

This collaborative effort underscores the commitment of stakeholders to addressing the challenge of Antimicrobial Resistance and enhancing infection prevention and control practices in healthcare settings.

By digitalizing AMS and IPC programs, the hospital aims to enhance patient safety, elevate clinical outcomes, and contribute to the global fight against Antimicrobial Resistance. This initiative exemplifies the potential of AI and ML in transforming healthcare delivery and advancing healthcare standards worldwide.

In another development, PD Hinduja Hospital launched CAR-T cell therapy with ImmunoACT for advanced medical care in January this year. This therapy uses NexCAR19, India's first gene-modified cell treatment. Developed by ImmunoACT in collaboration with IIT-Bombay and Tata Memorial Centre, NexCAR19 transforms T-cells into potent cancer fighters.

It specifically targets the CD19 protein, providing benefits to patients who were unresponsive to traditional treatments. This therapy is designed to address the needs of patients aged 15 and above with relapsed or refractory B-cell lymphoma and B-acute lymphoblastic leukemia.